Evidence map›Paper›PMID 26839890›Full record

ArticleJournal of diabetes research2016

Mechanism Investigation of the Improvement of Chang Run Tong on the Colonic Remodeling in Streptozotocin-Induced Diabetic Rats.

Hong Sha, Dong Zhao, Xiaolin Tong, Hans Gregersen, Jingbo Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Journal of traditional and complementary medicine · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hong ShaChina-Japan Hospital, Beijing 100029, China.
Dong ZhaoChina-Japan Hospital, Beijing 100029, China.
Xiaolin TongGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Hans GregersenBioengineering College of Chongqing University, Chongqing 400044, China.ORCID 0000-0002-5792-2845
Jingbo ZhaoBioengineering College of Chongqing University, Chongqing 400044, China; Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.
China-Japan Friendship Hospital · CNChongqing University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous study demonstrated that Chang Run Tong (CRT) could partly restore the colon remodeling in streptozotocin- (STZ-) induced diabetic rats. Here we investigated the mechanisms of such effects of CRT. Diabetes was induced by a single injection of 40 mg/kg of STZ. CRT was poured into the stomach by gastric lavage once daily for 60 days. The remodeling parameters were obtained from diabetic (DM), CRT treated diabetic (T1, 50 g/kg; T2, 25 g/kg), and normal (Con) rats. Expressions of advanced glycation end product (AGE), AGE receptor, transforming growth factor-β1 (TGF-β1), and TGF-β1 receptor in the colon wall were immunochemically detected and quantitatively analyzed. The association between the expressions of those proteins and the remodeling parameters was analyzed. The expressions of those proteins were significantly higher in different colon layers in the DM group (P < 0.05, P < 0.01) and highly correlated to the remodeling parameters. Furthermore, the expressions of those proteins were significantly decreased in the T1 group (P < 0.05, P < 0.01) but not in the T2 group (P > 0.05). The corrective effect on the expressions of those proteins is likely to be one molecular pathway for the improvement of CRT on the diabetes-induced colon remodeling.

Indexed as

StreptozocinAnimalsBlood GlucoseColonColonic DiseasesDiabetes ComplicationsDiabetes Mellitus, ExperimentalDrugs, Chinese HerbalGlycation End Products, AdvancedHypoglycemic AgentsMaleProtein Serine-Threonine KinasesRats, Sprague-DawleyReceptor for Advanced Glycation End ProductsReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IAger protein, ratBlood Glucosechang run tongDrugs, Chinese HerbalGlycation End Products, AdvancedHypoglycemic AgentsProtein Serine-Threonine KinasesReceptor for Advanced Glycation End ProductsReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IStreptozocinTgfb1 protein, ratTgfbr1 protein, ratTransforming Growth Factor beta1

Identifiers

PMID26839890
PMCPMC4709916
OpenAlexW2258192301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.